Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-K ☑ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended June 30, 2023 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from ________ to ________ Commission File Number: 1-11373 Cardinal Health, Inc. (Exact name of registrant as specified in its charter) (State or other jurisdiction o ...

Cardinal Health, Inc. (NYSE:CAH) Q3 2023 Earnings Conference Call May 4, 2023 8:30 AM ET Company Participants Kevin Moran - Vice President, Investor Relations Jason Hollar - Chief Executive Officer Aaron Alt - Chief Financial Officer Conference Call Participants Michael Cherny - Bank of America Lisa Gill - JPMorgan Kevin Caliendo - UBS Elizabeth Anderson - Evercore ISI Eric Percher - Nephron George Hill - Deutsche Bank Eric Coldwell - Baird Steven Valiquette - Barclays Daniel Grosslight - Citi Charles Rhyee ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION ☑ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2023 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from ________ to ________ Commission File Number: 1-11373 Cardinal Health, Inc. (Exact name of registrant as specified in its charter) (State or other jurisdiction of incorporation or organ ...

Financial Data and Key Metrics Changes - Total company revenue increased by 13% and gross margin increased by 3%, driven primarily by the Pharmaceutical segment [11] - Operating earnings were $467 million, consistent with the previous year, reflecting growth in the Pharma segment profit offset by a decline in Medical segment profit [11] - Earnings per share (EPS) grew by 4% to $1.32, with a diluted weighted average share count of 263 million, down 6% year-over-year due to share repurchases [12] Business Line Data and Key Metrics Changes - **Pharmaceutical Segment**: Revenue increased by 15% to $48 billion, with segment profit rising by 9% to $464 million, driven by growth in branded and specialty pharmaceutical sales [13][14] - **Medical Segment**: Revenue decreased by 7% to $3.8 billion, with segment profit declining by 66% to $17 million, primarily due to lower product and distribution sales [16] Market Data and Key Metrics Changes - Strong overall pharmaceutical demand was noted, particularly from large customers, with contributions from new customers and seasonal products [14] - The Medical segment experienced volume softness, but there was a slight improvement in PPE volumes sequentially [17] Company Strategy and Development Direction - The company is focused on three strategic priorities: executing the medical improvement plan, enhancing the growth of the Pharmaceutical segment, and maximizing shareholder value [10][22] - Investments are being made in expanding the Cardinal Health brand portfolio and optimizing supply chain operations to mitigate inflation impacts [24][25] - The company plans to hold an Investor Day on June 8th to discuss long-term financial outlook and growth strategies [29] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the resilience of the Pharmaceutical segment and anticipated gradual improvement in the Medical segment [21] - The company raised its EPS guidance for fiscal 2023, reflecting improved outlooks for the Pharmaceutical segment and interest income [18] - Management acknowledged ongoing inflationary pressures but noted effective mitigation actions, expecting to exit the year with at least 50% inflation mitigation [20][23] Other Important Information - The company completed a $1 billion accelerated share repurchase program and initiated a new $250 million program, with expectations of $1.5 billion to $2 billion in share repurchases for fiscal 2023 [12] - The company reported a cash position of $3.7 billion with no outstanding borrowings on its credit facility [13] Q&A Session All Questions and Answers Question: Expectations around surgical procedures and staffing issues - Management acknowledged constraints impacting growth in the Medical segment and anticipated gradual improvement in volumes as staffing issues resolve [32][33] Question: Pharma improvement and interest expense guidance - Management indicated that the improvement in the Pharma segment is primarily driven by volume, with interest expense guidance reflecting changes in cash balances rather than significant differences in interest rates [40][41][42] Question: Concerns or headwinds built into EPS guidance - Management provided a balanced outlook, noting that while the Pharma segment is expected to grow, the Medical segment has areas of concern that need to be monitored [45][47][56] Question: Opportunities in COVID treatments and core Pharma segment - Management noted limited participation in COVID treatments but indicated potential opportunities for 2024 and beyond as commercialization opens up [50][52] Question: Pricing and customer receptivity in Med/Surg - Management discussed a consistent approach to pricing adjustments and the desire to work collaboratively with customers to address challenges [61][62] Question: Size and growth of the at-home solutions business - Management confirmed that the at-home solutions business generated $2.4 billion in revenue last year, with approximately 9% growth in the first two quarters [68]

Q2 FY23 Cardinal Health, Inc. Earnings Call Forward-looking statements and GAAP reconciliation Cautions Concerning Forward-Looking Statements This presentation contains forward-looking statements addressing expectations, prospects, estimates and other matters that are dependent upon future events or developments. These statements may be identified by words such as "expect," "anticipate," "intend," "plan," "believe," “will," "should," "could," "would," "project," "continue,” "likely," and similar expressions ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q ☑ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended December 31, 2022 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from ________ to ________ Commission File Number: 1-11373 Cardinal Health, Inc. (Exact name of registrant as specified in its charter) (State or other ju ...

Cardinal Health Inc. 41st Annual JP Morgan Conference January 9, 2023 Jason Hollar Chief Executive Officer ...

Cardinal Health, Inc. (NYSE:CAH) Q1 2023 Earnings Conference Call November 4, 2022 8:30 AM ET Company Participants Kevin Moran - Vice President of Investor Relations Jason Hollar - Chief Executive Officer Trish English - Interim Chief Financial Officer Conference Call Participants Elizabeth Anderson - Evercore Lisa Gill - JPMorgan Kevin Caliendo - UBS Erin Wright - Morgan Stanley Michael Cherny - Bank of America Eric Percher - Nephron Research George Hill - Deutsche Bank A.J. Rice - Credit Suisse Charles Rh ...